Partnership Expansion Recent collaborations with the University of Southern California, Keck Medicine, and Hull University Teaching Hospitals NHS Trust, in coordination with Novartis, show a pattern of partnering academic centers and health systems to address cancer care pathways and diagnostics. This creates a sales opportunity to target large hospital networks with radiopharmaceuticals, companion diagnostics, and imaging services, offering joint programs, training, and service level arrangements.

Global Radiopharma Reach Novartis activity includes Pluvicto launches in India and ongoing radiopharmaceutical momentum, signaling room to expand into emerging markets through regional partnerships, local manufacturing, and regulatory support. There is an opportunity to pursue regional go to market strategies for Lutathera and Pluvicto, leveraging the Novartis global footprint and distribution networks.

Digital Enablement The disclosed tech stack includes Azure Analysis Services, OneStream, QAD ERP, SAP Procurement, and OpenStack, indicating readiness for data driven care and optimized operations. Sales opportunities include offering analytics, integration services, and procurement supply chain optimization to health systems and to internal teams within the Novartis ecosystem.

IP and Licensing Patent activity and litigation around Lu-177 radiopharmaceuticals highlight a need for licensing strategies and collaboration to reduce risk in portfolios. Potential opportunities include licensing deals, co development arrangements, or cross licensing with industry partners to broaden access to Lu-177 based therapies and related diagnostics.

Financial Leverage With moderate revenue and external funding, there is capacity to invest and scale partnerships with hospitals, universities, and government programs. This can support joint ventures, early access programs, and manufacturing or distribution expansions for radiopharmaceuticals and related services.